Novartis exec pushed out over Zolgensma data scandal denies wrongdoing
pharmafile | August 21, 2019 | News story | Research and Development | AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma
Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement that he “categorically denies any wrongdoing.”
Speaking through a lawyer, Kaspar said he “stands proudly behind the safety and efficacy” of the $2.1 million gene therapy Zolgensma, and that he is “prepared to assert his rights and defend his conduct accordingly.”
The statement from law firm Heuston Hannigan, who previously represented Elon Musk, says: “Dr Brian Kaspar is a respected member of the scientific community with an impeccable record. He stands proudly behind the safety and efficacy of the drug that he and his team worked so hard to develop, and which remains an FDA-approved drug that is saving the lives of children who suffer from Spinal Muscular Atrophy.
“He has cooperated with Avexis’ internal investigation, and he categorically denies any wrongdoing. He is prepared to assert his rights and defend his conduct accordingly. Dr Kaspar continues to wish clinicians and the company continued success in the treatment of children with this deadly and devastating disease.”
Louis Goss
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …